
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted Bavarian Nordic a positive opinion to extend smallpox vaccine Imvanex’s indication to include monkeypox, the firm reported Friday.
Now, the only thing standing in the way of the vaccine’s official use to ward off monkeypox in the region is the EU Commission, which has the final say in matters of drug authorization.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app